



May 20, 2026

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip code: STAR

Scrip code: 532531

Dear Madam/ Sir,

Reg: Disclosure under Regulation 30 of SEBI Listing Regulations

Sub: Completion of US-FDA Inspection at the Company's flagship facility in Bangalore

We hereby notify that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Company's flagship facility in Bangalore during the period **from May 12, 2026 to May 20, 2026**.

At the conclusion of the inspection, the U.S. FDA has issued a Form 483 with five observations.

Company will respond to these observations to FDA within the stipulated time.

We will keep the stock exchanges informed if there is any further update in this matter.

Please take the above information on record.

Thanks & Regards,

For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary
ICSI Membership No. A30515

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: 'Cyber One', Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India |

Tel: +91 22 2789 2924/3199

corpcomm@strides.com; www.strides.com